Cargando…

Temozolomide in paediatric high-grade glioma: a key for combination therapy?

This report describes a single-centre study with temozolomide (TMZ) (200 mg m(−2) day(−1) × 5 per cycle of 28 days) in children with (recurrent) high-grade glioma. Magnetic resonance imaging was performed every two cycles. In all, 20 patients were treated between 1998 and 2001 after the UKCCSG/SFOP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verschuur, A C, Grill, J, Lelouch-Tubiana, A, Couanet, D, Kalifa, C, Vassal, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409857/ https://www.ncbi.nlm.nih.gov/pubmed/15266331 http://dx.doi.org/10.1038/sj.bjc.6601997

Ejemplares similares

Dose finding and O(6)-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies
por: Geoerger, B, et al.
Publicado: (2005)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Comprehensive analysis of HHV‐6 and HHV‐7‐related gene signature in prognosis and response to temozolomide of glioma
por: Chen, Luoyi, et al.
Publicado: (2022)

Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
por: Doireau, V, et al.
Publicado: (1999)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2018)

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
por: Murphy, P S, et al.
Publicado: (2004)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis
por: Li, Guanglie, et al.
Publicado: (2023)

Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations
por: Boland, I, et al.
Publicado: (1999)

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide
por: Koekkoek, Johan A. F., et al.
Publicado: (2015)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
por: Ohba, Shigeo, et al.
Publicado: (2021)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

β-elemene combined with temozolomide in treatment of brain glioma
por: Zhang, Xiaomin, et al.
Publicado: (2021)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy
por: Zhou, Xiaofeng, et al.
Publicado: (2016)

Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication
por: Tanaka, Fumiaki, et al.
Publicado: (2023)

Utility of Tissue Similarity Maps Based on Relative Cerebral Blood Volume for Grading Gliomas as Validated by Histological Results
por: Hu, Su, et al.
Publicado: (2015)

Identification of purity and prognosis‐related gene signature by network analysis and survival analysis in brain lower grade glioma
por: Xiong, Zujian, et al.
Publicado: (2020)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
por: McDuff, Susan G. R., et al.
Publicado: (2019)

Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis
por: Xu, Weilin, et al.
Publicado: (2017)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
por: Wan, Yanzhi, et al.
Publicado: (2023)

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy
por: Guillevin, R, et al.
Publicado: (2011)

Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma
por: Simpson, Aaron D., et al.
Publicado: (2019)

Familial diagnostic experiences in paediatric oncology
por: Evans, N T, et al.
Publicado: (2015)

Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma
por: Salas, Lucas A., et al.
Publicado: (2022)

NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
por: Rocha, Clarissa Ribeiro Reily, et al.
Publicado: (2016)

Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
por: Mazzocco, P, et al.
Publicado: (2015)

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
por: Shi, Hui, et al.
Publicado: (2020)

Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma
por: Wei, Shoufeng, et al.
Publicado: (2022)

Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
por: Lam, Fred C., et al.
Publicado: (2018)

Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy; A Review Article
por: Koukourakis, Georgios V., et al.
Publicado: (2009)

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas
por: Lamb, Lawrence S., et al.
Publicado: (2021)

PAEDIATRIC-12 MANAGEMENT OF PAEDIATRIC LOW-GRADE GLIOMA IN CAPE TOWN, SOUTH AFRICA
por: Tsimane, Katlego, et al.
Publicado: (2023)

Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma
por: Karremann, M, et al.
Publicado: (2013)

ACT-18 SHOULD THE DOSE OF TEMOZOLOMIDE BE DECREASED FOR PATIENTS WITH HIGH-GRADE GLIOMAS WHO ARE ON HEMODIALYSIS?
por: Muto, Jun, et al.
Publicado: (2019)

Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients
por: Zhang, Baiwei, et al.
Publicado: (2021)

Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma
por: Zhong, Liyun, et al.
Publicado: (2022)

Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas
por: Tu, Zewei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jcbmo1b4n463tnolf3c2oal9ps